Everything below concerns clinical evidence. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentadecapeptide | Fifteen amino acids; sequence matches a fragment of a gastric juice protein |
| Molecular formula | C62H98N16O22 | Corresponds to a molecular mass near 1419 Da |
| Primary origin | Fragment of human gastric juice protein BPC | First characterized in the early 1990s |
| Common synonyms | BPC 157; PL 14736; pentadecapeptide BPC 157 | Naming conventions vary across publications |
| Reported stability | Stable in gastric juice during in vitro incubation | Based on laboratory incubation, not clinical data |
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
== Awards == 2013, International Society for Molecular Recognition (ISMR) 2015, Janne Carlsson's prize for academic leadership, KTH 2022, The Westrup prize, The Royal Physiographic Society of Lund 2022, Alum of the Year, KTH
In November 2025, the case was discontinued and all charges against the protesters were dropped as the Crown Prosecution Service and Met Police decided the evidence did not meet the evidentiary threshold for a prosecution.
== Second reconstruction (1941–1958) == A second reconstruction was carried out between 1941 and 1958, initiated by François Jourda de Vaux de Foletier (1893–1988), director of the Seine Archives. This effort, referred to as the "second reconstruction," primarily used documents donated by families, biographical works, and dictionaries. It includes over 400 boxes, organized alphabetically by family name, and classified into births, marriages (listed only under the husband’s name), and deaths. The Archives of Paris continue to receive records or copies of documents to supplement the civil records. These contributions usually come from individuals who uncover materials during their research, effectively extending the "second reconstruction" of Parisian civil records.
Sources: en.wikipedia.org
Angiolymphoid hyperplasia with eosinophilia (epithelioid hemangioma, histiocytoid hemangioma, inflammatory angiomatous nodule, inflammatory arteriovenous hemangioma, intravenous atypical vascular proliferation, papular angioplasia, pseudopyogenic granuloma) Annular erythema of infancy Arthropod assault Eosinophilic cellulitis (Wells' syndrome) Eosinophilic fasciitis (Shulman's syndrome) Eosinophilic granuloma Eosinophilic granulomatosis with polyangiitis Eosinophilic pustular folliculitis of infancy (eosinophilic pustular folliculitis in infancy, infantile eosinophilic pustular folliculitis, neonatal eosinophilic pustular folliculitis) Eosinophilic ulcer of the oral mucosa (eosinophilic ulcer of the tongue, Riga–Fede disease, traumatic eosinophilic granuloma) Eosinophilic vasculitis Erythema toxicum neonatorum (erythema toxicum, toxic erythema of the newborn) Granuloma faciale Hypereosinophilia Hypereosinophilic syndrome Incontinentia pigmenti (Bloch–Siemens syndrome, Bloch–Sulzberger disease, Bloch–Sulzberger syndrome) Itchy red bump disease (papular dermatitis) Juvenile xanthogranuloma Kimura's disease Nodules–eosinophilia–rheumatism–dermatitis–swelling syndrome Pachydermatous eosinophilic dermatitis Papular eruption of blacks Papuloerythroderma of Ofuji Pruritic papular eruption of HIV disease
=== Focused shockwave therapy === Focused shockwave therapy involves passing short, high frequency acoustic pulses through the skin and into the penis. These waves break down any plaques within the blood vessels, encourage the formation of new vessels, and stimulate repair and tissue regeneration. Focused shockwave therapy appears to work best for males with vasculogenic ED, which is a blood vessel disorder that affects blood flow to tissue in the penis. The treatment is painless and has no known side effects. Treatment with shockwave therapy can lead to a significant improvement of the IIEF (International Index of Erectile Function).
=== Gott ist schön (dissertation 1998) === In his dissertation Gott ist schön (God is Beautiful), which focuses on reception aesthetics and philology, Kermani shows how prominently Islamic tradition perceives the aesthetic dimension of the Koran. The Koran is described as a beguiling, captivating work of art, its beauty capturing people's hearts with an irresistible appeal. The beauty and clarity of the Koran is thus proof of its divine inspiration. According to this conception, God communicates in the Koran in an aesthetically mediated way in hopes to be understood accordingly by those whom the Koran addresses. If God seeks understanding recognition rather than blind obedience, he must encounter receptive people in an aesthetic way. For—at least according to Navid Kermani's thesis informed by his analytical view of Islamic tradition—religious recognition in Islam is conveyed aesthetically as the thrilling, goose bump-inducing hearing of a language described as beautiful, i.e. as an experience of beauty. Kermani is therefore concerned with appreciating the power of aesthetics on a religious level. He views this mystical insight as being entirely in line with the more recent Western aesthetics since Hegel. In almost all philosophical theories of art in the modern tradition, aesthetic experience is about truth. Indeed, contrary to Kant, aesthetic experience need not be about enjoyment or disinterested pleasure. It may simply be about discovering the truth, whatever the cost.
Sources: en.wikipedia.org
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.
The letters abbreviate body protection compound, the name given to the parent protein isolated from gastric juice. The number is an identifier attached to the specific fragment, not a dose or a description of a chemical property.
The sequence corresponds to a segment of an endogenous gastric protein, but the isolated fifteen-amino-acid peptide is a synthetic construct. Whether the free fragment circulates in humans at measurable levels is not clearly established in the published literature.
Lyophilised peptide powders are generally kept frozen or refrigerated, dry, and protected from light. Sealed vials limit moisture uptake and slow hydrolysis. Such guidance comes from general peptide chemistry rather than from stability studies specific to every product.